Modality
Small Molecule
MOA
FcRni
Target
LAG-3
Pathway
RAS/MAPK
T2D
Development Pipeline
Preclinical
Jan 2017
→ Jul 2028
PreclinicalCurrent
NCT07010182
1,925 pts·T2D
2017-01→2025-12·Recruiting
NCT04505634
2,014 pts·T2D
2018-03→2028-07·Completed
3,939 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-243mo agoInterim· T2D
2028-07-272.3y awayInterim· T2D
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Recruit…
Preclinical
Complet…
Catalysts
Interim
2025-12-24 · 3mo ago
T2D
Interim
2028-07-27 · 2.3y away
T2D
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07010182 | Preclinical | T2D | Recruiting | 1925 | VA |
| NCT04505634 | Preclinical | T2D | Completed | 2014 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| STO-2663 | Stoke Ther | Approved | LAG-3 |